DAVID F. WELCH, PH.D.

Corporate Board Profile

Tech Score: 50/100

← Back to All Directors

Software Technology Evidence

1 mention(s) identify DAVID F. WELCH, PH.D. as having software/technology expertise.

Company Filing Date Evidence Reason
CytoDyn Inc. 2019-08-21 Dr. Welch was named the Chief Innovation Officer of Infinera Corporation, a company which he co-founded. He served as Chief Strategy and Technology Officer, President, Executive Vice President and Chief Strategy Officer, and Chief Development Officer/CTO. He holds a B.S. in Electrical Engineering from the University of Delaware and a Ph.D. in Electrical Engineering from Cornell University. Dr. Welch holds over 130 patents and has been awarded multiple technical awards. Dr. Welch has extensive technical and engineering experience including serving as Chief Technology Officer and Chief Development Officer at technology companies, holds a Ph.D. in Electrical Engineering, and holds over 130 patents, indicating strong software and technical skills.

CytoDyn Inc.

Filing Date Source Excerpt
2019-08-21 Dr. Welch was named the Chief Innovation Officer of Infinera Corporation, a company which he co-founded. He served as Chief Strategy and Technology Officer, President, Executive Vice President and Chief Strategy Officer, and Chief Development Officer/CTO. He holds a B.S. in Electrical Engineering from the University of Delaware and a Ph.D. in Electrical Engineering from Cornell University. Dr. Welch holds over 130 patents and has been awarded multiple technical awards.
2020-06-22 David F. Welch, Ph.D. (4) Includes: (i) 9,513,417 shares of Common Stock, 1,000 shares of Series D Convertible Preferred Stock convertible into 1,250,000 shares of Common Stock and a warrant covering 500,000 shares of Common Stock held by a limited liability company for which Dr. Welch is the managing member and has voting and dispositive power; (ii) 3,002,202 shares of Common Stock held directly by a trust for which Dr. Welch, as trustee, has voting and dispositive power; and (iii) 1,295,154 shares of Common Stock subject to options held directly by Dr. Welch.

Data sourced from SEC filings. Last updated: 2026-02-03